Skip to content
value.today

PhaseBio Pharmaceuticals Inc

Total raised
$102 M
4 rounds on record
Latest round
$26 M
Aug 2018
First round on record
Dec 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of PhaseBio Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2018$26 MNo. 4$10 to $50 million

PhaseBio Pharmaceuticals Inc: Raise no. 4, Aug 2018

Investors in this round

20 investors had bought by the notice of Sep 10, 2018: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for PhaseBio Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $32 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Offer and sale of Series D Preferred Stock and warrants to purchase Series C-1 Preferred Stock, and the underlying shares of Common Stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Sharp · Executive Officer
  • Jonathan Mow · Executive Officer, Director
  • Bibhash Mukhopadhyay · Director
  • Caroline Loewy · Director
  • Clay Thorp · Director
  • Justin Klein · Director
  • Linda Tufts · Director
  • Nancy Hutson · Director
  • Tyrell Rivers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes the value of cancelled indebtedness formerly held by certain purchasers in the aggregate principal amount of $8,085,000.00.”

Signed by John Sharp, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2018. Read the notice at the SEC.

equity, optionsSEC
Jan 2017$7 MNo. 3$2 to $10 million

PhaseBio Pharmaceuticals Inc: Raise no. 3, Jan 2017

Investors in this round

9 investors had bought by the notice of Jan 31, 2017: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for PhaseBio Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $8 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Offer and sale of convertible promissory notes and warrants to purchase preferred stock, and the underlying shares of preferred stock and common stock issuable upon conversion or exercise thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Sharp · Executive Officer
  • Jonathan Mow · Executive Officer, Director
  • Ashutosh Chilkoti · Director
  • Asish K. Xavier · Director
  • Clay Thorp · Director
  • Guy K. Fish · Director
  • James K. Barrett · Director
  • Justin K. Klein · Director
  • Michael K. Gutch · Director
  • Robert K. Ingram · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by John Sharp, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 31, 2017. Read the notice at the SEC.

debt, optionsSEC
Feb 2015$21 MNo. 2$10 to $50 million

PhaseBio Pharmaceuticals Inc: Raise no. 2, Feb 2015

Investors in this round

9 investors had bought by the notice of Jul 21, 2015: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for PhaseBio Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $42 M offered; $21 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Offer and sale of Series C Preferred Stock, and the underlying shares of Common Stock issuable upon conversion thereof
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$900,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Joel Sussman · Executive Officer
  • Jonathan Mow · Executive Officer, Director
  • Ashutosh Chilkoti · Director
  • Asish K. Xavier · Director
  • Clay Thorp · Director
  • Guy K. Fish · Director
  • James K. Barrett · Director
  • Justin K. Klein · Director
  • Michael K. Gutch · Director
  • Robert K. Ingram · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Joel Sussman, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 21, 2015. Read the notice at the SEC.

equitySEC
Dec 2009$49 MNo. 1$10 to $50 million

PhaseBio Pharmaceuticals Inc: Raise no. 1, Dec 2009

Investors in this round

17 investors had bought by the notice of Jun 18, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for PhaseBio Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$49 M of $49 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ashutosh Chilkoti · Executive Officer, Director
  • Christopher Prior · Executive Officer, Director
  • Joel Sussman · Executive Officer
  • Asish K Xavier · Director
  • Clay Thorp · Director
  • Craig K Rosen · Director
  • Guy K Fish · Director
  • James K Barrett · Director
  • Justin K Klein · Director
  • Robert K Ingram · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”

Signed by Christopher Prior, Ph.D., Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Jun 18, 2012. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • PhaseBio Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Sep 2018).

    SEC Form D · Sep 2018

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2018

That is all the official record says: PhaseBio Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in PhaseBio Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Astrazeneca PLCCompanynot statednot statedHeld Series C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Catalysta Ventures, LLCVenture capitalnot statednot statedHeld Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Hatteras Venture Advisors III, LLCVenture capitalnot statednot statedHeld Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Hatteras Venture Affiliates III LpVenture capitalnot statednot statedHeld Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Hatteras Venture Partners I, LPVenture capitalnot statednot statedHeld Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Hatteras Ventures Partners III LPVenture capitalnot statednot statedHeld Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
NEA 13 GP, LtdCompanynot statednot statedHeld Series B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
NEA Partners 13, Limited PartnershipFund or asset managernot statednot statedHeld Series B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
New Enterprise Associates 13 LPFund or asset managernot statednot statedHeld Series B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Peter Justin KleinPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2018)SEC Form 3
Susan Elizabeth ArnoldPersonnot statednot statedHeld Series B preferred stock (Form 3, 2018)SEC Form 3
Venture Capital Multiplier FundVenture capitalnot statednot statedHeld Series AA, B, C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Zeneca, Inc.Companynot statednot statedHeld Series C-1 and D preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by PhaseBio Pharmaceuticals Inc
NameRoleNamed in
John SharpExecutive officerSep 2018
Jonathan MowExecutive officerSep 2018
Joel SussmanExecutive officerJul 2015
Ashutosh ChilkotiExecutive officerJun 2012
Christopher PriorExecutive officerJun 2012
Thomas K LaundonExecutive officerJan 2010
Bibhash MukhopadhyayDirectorSep 2018
Caroline LoewyDirectorSep 2018
Clay ThorpDirectorSep 2018
Jonathan MowDirectorSep 2018
Justin KleinDirectorSep 2018
Linda TuftsDirectorSep 2018
Nancy HutsonDirectorSep 2018
Tyrell RiversDirectorSep 2018
Ashutosh ChilkotiDirectorJan 2017
Asish K. XavierDirectorJan 2017
Guy K. FishDirectorJan 2017
James K. BarrettDirectorJan 2017
Justin K. KleinDirectorJan 2017
Michael K. GutchDirectorJan 2017
Robert K. IngramDirectorJan 2017
Asish K XavierDirectorJun 2012
Christopher PriorDirectorJun 2012
Craig K RosenDirectorJun 2012
Guy K FishDirectorJun 2012
James K BarrettDirectorJun 2012
Justin K KleinDirectorJun 2012
Robert K IngramDirectorJun 2012
Ashutosh K ChilkotiDirectorJan 2010
Clay K ThorpDirectorJan 2010
Douglas K ReedDirectorJan 2010